Product Liability

National Prescription Opiate / Opioid Litigation

National Prescription Opiate / Opioid Litigation — Product Liability class action lawsuit

Case Overview

The National Prescription Opiate Litigation, coordinated as MDL No. 2804 in the Northern District of Ohio, became one of the largest and most complex mass tort cases in U.S. history. Thousands of plaintiffs — including state attorneys general, counties, cities, and Native American tribes — alleged that pharmaceutical manufacturers like Johnson & Johnson aggressively and deceptively marketed opioid painkillers as safe and non-addictive, while distributors like McKesson, AmerisourceBergen, and Cardinal Health (the "Big Three") ignored obvious red flags and flooded communities with billions of pills. The opioid epidemic has claimed over 500,000 American lives since 1999, devastating families and straining public health and law enforcement resources nationwide.

After years of litigation and bellwether trials, the case produced a landmark $26 billion settlement in 2021 with the three major distributors and Johnson & Johnson, one of the largest civil settlements in U.S. history. The funds are being distributed over 18 years and are earmarked specifically for addiction treatment, recovery programs, and prevention efforts. Additional settlements followed with pharmacy chains including CVS, Walgreens, and Walmart, bringing total opioid settlement dollars to well over $50 billion. The case set a powerful legal and legislative precedent for corporate accountability in the public health crisis.

Frequently Asked Questions

Am I eligible to receive money from the opioid settlement?

Eligibility depends on whether your state, local government, or tribal nation was part of the settlement, and what claims category you fall under. Governments, hospitals, and certain individuals harmed by opioids may be eligible. Check the settlement website or contact your state attorney general's office to determine your specific eligibility.

How much money will I get from the Johnson & Johnson and opioid distributor settlement?

The total settlement is worth $26 billion, but individual payouts vary based on the claimant category (state governments, local governments, tribes, healthcare providers, or individuals) and the number of approved claims. Exact amounts depend on the settlement administrator's allocation formula and will be distributed over multiple years.

Can I sue Johnson & Johnson and opioid distributors for the opioid crisis?

The landmark settlement resolves most litigation against these defendants, so individual lawsuits are largely prohibited once you're bound by the settlement. However, if you haven't opted out and believe you have a valid claim, you should consult an attorney immediately, as deadlines to opt out may have passed.

Related Cases

Hair Relaxer Cancer Lawsuit Investigation — Product Liability class action lawsuit

Hair Relaxer Cancer Lawsuit Investigation

Current
Product Liability
This legal matter involves allegations that chemicals in hair relaxers and straighteners may increase the risk of certain gynecological cancers in women. Thousands of individuals have filed claims against major beauty companies regarding this issue.
Gerber and Baby Food Makers Autism MDL Partial Summary Judgment — Product Liability class action lawsuit

Gerber and Baby Food Makers Autism MDL Partial Summary Judgment

Current
Product Liability
Baby food manufacturers, including Gerber, have won a partial summary judgment in a multidistrict litigation concerning claims that heavy metals in their products caused autism or ADHD in children.
Gabapentin and Pregabalin Cognitive Impairment Investigation — Product Liability class action lawsuit

Gabapentin and Pregabalin Cognitive Impairment Investigation

Current
Product Liability
Attorneys are investigating whether manufacturers of gabapentin (Neurontin) and pregabalin (Lyrica) failed to warn consumers about a potential link between long-term use of these medications and cognitive decline. Individuals diagnosed with early-onset dementia or cognitive impairment after taking these drugs may be eligible to seek compensation.